COATES; David Andrew

Patent Applications and Registrations

Patent applications and USPTO patent grants for COATES; David Andrew.The latest application filed is for "salts of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one compound as erk inhibitors".

Company Profile

21.23.34

COATES; David Andrew - New Palestine IN
Coates; David Andrew - England GB
Coates; David Andrew - Indianapolis IN
Coates; David Andrew - Nottingham England
Coates; David Andrew - West Lafayette IN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Salts Of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one Compound As Erk Inhibitors App 20220153750 - COATES; David Andrew ; et al.	2022-05-19
Il-17a Inhibitors App 20220073526 - Coates; David Andrew ; et al.	2022-03-10
Disubstituted Pyrazole Compounds App 20220017496 - COATES; David Andrew ; et al.	2022-01-20
Disubstituted pyrazole compounds Grant 11,124,500 - Coates , et al. September 21, 2	2021-09-21
CGRP receptor antagonists Grant 11,066,386 - Coates , et al. July 20, 2	2021-07-20
Electroacoustic driver and related loudspeaker/sounder Grant 11,012,785 - Coates May 18, 2	2021-05-18
KRas G12C inhibitors Grant 10,968,214 - Barda , et al. April 6, 2	2021-04-06
Condensed thiophene derivatives useful as NaPi-IIb inhibitors Grant 10,934,280 - Coates , et al. March 2, 2	2021-03-02
(e)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-- Carboxylate For Inhibiting Cdk7 App 20210032257 - COATES; David Andrew ; et al.	2021-02-04
Glucagon-like Peptide1 Receptor Agonists App 20200407347 - COATES; David Andrew ; et al.	2020-12-31
Disubstituted Pyrazole Compounds App 20200392118 - COATES; David Andrew ; et al.	2020-12-17
Amino pyrimidine ssao inhibitors Grant 10,793,552 - Coates , et al. October 6, 2	2020-10-06
(E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-- carboxylate for inhibiting CDK7 Grant 10,787,460 - Coates , et al. September 29, 2	2020-09-29
Amino Pyrimidine Ssao Inhibitors App 20200262817 - COATES; David Andrew ; et al.	2020-08-20
Cgrp Receptor Antagonists App 20200181111 - Coates; David Andrew ; et al.	2020-06-11
Kras G12c Inhibitors App 20200115375 - BARDA; David Anthony ; et al.	2020-04-16
Dopamine D1 receptor positive allosteric modulators Grant 10,611,751 - Hilliard , et al.	2020-04-07
Condensed Thiophene Derivatives Useful As Napi-iib Inhibitors App 20200031813 - Coates; David Andrew ; et al.	2020-01-30
(e)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-- C App 20200017513 - COATES; David Andrew ; et al.	2020-01-16
Amino pyrimidine SSAO inhibitors Grant 10,464,928 - Coates , et al. No	2019-11-05
Electroacoustic Driver Housing Element App 20190327546 - Coates; David Andrew ; et al.	2019-10-24
Dopamine D1 Receptor Positive Allosteric Modulators App 20190322639 - Hilliard; Darryl Wayne ; et al.	2019-10-24
Amino Pyrimidine Ssao Inhibitors App 20190276436 - COATES; David Andrew ; et al.	2019-09-12
Electroacoustic Driver And Related Loudspeaker/sounder App 20190268700 - Coates; David Andrew	2019-08-29
Pyrazolylaminobenzimidazole derivatives as JAK inhibitors Grant 10,323,019 - Bastian , et al.	2019-06-18
Pyrazolylaminobenzimidazole Derivatives As Jak Inhibitors App 20190177300 - Bastian; Jolie Anne ; et al.	2019-06-13
Compounds Useful For Inhibiting Cdk7 App 20190144456 - Coates; David Andrew ; et al.	2019-05-16
Amino pyrimidine SSAO inhibitors Grant 10,287,270 - Coates , et al.	2019-05-14
N-[3-[2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxa- Zin-7a-yl]-4-fluoro-phenyl-5-(trifluoromethyl)pyridine-2-carboxamide And Its (4ar,5s,7as) Isomer As A Selective Bace1 Inhibitor For Treating E.g. Alzheimer's Disease App 20190106434 - Coates; David Andrew ; et al.	2019-04-11
Pyrazolylaminobenzimidazole Derivatives As Jak Inhibitors App 20180325873 - Bastian; Jolie Anne ; et al.	2018-11-15
Amino Pyrimidine Ssao Inhibitors App 20180297987 - Coates; David Andrew ; et al.	2018-10-18
Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyr- rolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carbo- xamide Grant 10,080,758 - Coates , et al. September 25, 2	2018-09-25
2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives Grant 9,920,056 - Beauchamp , et al. March 20, 2	2018-03-20
Tosylate Salt Of N-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyr- Rolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carbo- Xamide App 20170368071 - Coates; David Andrew ; et al.	2017-12-28
Tetrahydropyrrolo[3,4-D][1,3]thiazine-derivative as BACE inhibitor Grant 9,828,390 - Coates , et al. November 28, 2	2017-11-28
A Tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative As Bace Inhibitor App 20170233410 - COATES; David Andrew ; et al.	2017-08-17
CGRP receptor antagonists Grant 9,708,297 - Coates , et al. July 18, 2	2017-07-18
CGRP receptor antagonists Grant 9,637,495 - Coates , et al. May 2, 2	2017-05-02
Cgrp Receptor Antagonists App 20170044138 - Coates; David Andrew ; et al.	2017-02-16
Cgrp Receptor Antagonists App 20170044163 - Coates; David Andrew ; et al.	2017-02-16
2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] Carboxylic Acid Derivatives App 20160368922 - Beauchamp; Thomas James ; et al.	2016-12-22
Methods For Improving Chicken Production App 20150203471 - Aissat; Djamel ; et al.	2015-07-23
3,4-dihydroisoquinolin-2(1H)-yl compounds Grant 8,962,654 - Beadle , et al. February 24, 2	2015-02-24
3,4-dihydroisoquinolin-2(1h)-yl Compounds App 20140357664 - BEADLE; Christopher David ; et al.	2014-12-04
SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS App 20140275049 - Bleisch; Thomas John ; et al.	2014-09-18
Mineralocorticoid receptor antagonist and methods of use Grant 8,658,638 - Coates , et al. February 25, 2	2014-02-25
Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylp- ropanoic acid compounds as dual activity H1 inverse agonists/5-HT.sub.2A antagonists Grant 8,314,092 - Camp , et al. November 20, 2	2012-11-20
Oxazolo[5-4-b]pyridin-5-yl compounds Grant 8,288,548 - Coates , et al. October 16, 2	2012-10-16
SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLP- ROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS App 20120202797 - CAMP; Anne Marie ; et al.	2012-08-09
OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS App 20120142724 - Coates; David Andrew ; et al.	2012-06-07
Mineralocorticoid Receptor Antagonist And Methods Of Use App 20110312954 - Coates; David Andrew ; et al.	2011-12-22
Crystalline Forms Of [R-(R,R)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1) App 20080287521 - Byrn; Stephen Robert ; et al.	2008-11-20
Crystalline forms of [R-(R, R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- -[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) App 20080214651 - Byrn; Stephen Robert ; et al.	2008-09-04
Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- -3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) Grant 7,144,915 - Byrn , et al. December 5, 2	2006-12-05
Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5- -(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) App 20040054193 - Byrn, Stephen Robert ; et al.	2004-03-18
Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) Grant 6,605,729 - Byrn , et al. August 12, 2	2003-08-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.